GlassScriptPhysician profile
Amy L Jankowski
NPI 1174518161
$3,657.65
in general payments reported to CMS, 2019-2025
16 companies · $637 in 2025
The $637 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $442 · 2021: $876 · 2022: $492 · 2023: $548 · 2024: $551 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324 · Consulting Fee: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.32 |
| Consulting Fee | $410.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,374.31 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,216.24 | 2019-2025 | Dailies Total1, Rocklatan, Total30 |
| Abbvie INC. | $228.12 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $143.02 | 2020-2023 | |
| Oyster Point Pharma, INC. | $141.86 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $125.38 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Harrow Eye, LLC | $84.16 | 2024-2025 | Vevye |
| Allergan, INC. | $71.02 | 2021 | |
| Abb Con-Cise Optical Group LLC | $49.41 | 2022 | |
| Kala Pharmaceuticals, INC. | $45.48 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.97 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $39.63 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $31.87 | 2019-2020 | |
| Dompe US, INC. | $28.21 | 2024 | Oxervate |
| Coopervision INC. | $18.52 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $18.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Jankowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.